XML 54 R43.htm IDEA: XBRL DOCUMENT v3.25.3
SEGMENT INFORMATION (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2024
USD ($)
SEGMENT INFORMATION                
Number of reportable segment | segment             1  
Revenues       $ 2,261,642       $ 11,139,956
Research and development:                
Total research and development $ 20,359,098     11,807,867     $ 61,321,924 35,413,649
General and administrative:                
General and Administrative Expense, Total 5,924,942     3,463,655     17,664,198 10,593,308
LOSS FROM OPERATIONS (26,284,040)     (13,009,880)     (78,986,122) (34,867,001)
Total non-operating income, net 1,713,393     453,152     4,113,090 1,516,418
NET LOSS (24,570,647) $ (25,910,791) $ (24,391,594) (12,556,728) $ (10,999,782) $ (9,794,073) (74,873,032) (33,350,583)
Single reportable segment                
SEGMENT INFORMATION                
Revenues       2,261,642       11,139,956
Research and development:                
Total research and development 20,359,098     11,807,867     61,321,924 35,413,649
General and administrative:                
Compensation and benefits 3,314,529     2,323,384     11,672,488 7,516,797
Other G&A segment expenses 2,610,413     1,140,271     5,991,710 3,076,511
General and Administrative Expense, Total 5,924,942     3,463,655     17,664,198 10,593,308
LOSS FROM OPERATIONS (26,284,040)     (13,009,880)     (78,986,122) (34,867,001)
Total non-operating income, net 1,713,393     453,152     4,113,090 1,516,418
NET LOSS (24,570,647)     (12,556,728)     (74,873,032) (33,350,583)
Single reportable segment | Compensation and benefits                
Research and development:                
Total research and development 9,586,659     4,461,233     27,176,680 13,314,847
Single reportable segment | Duchenne muscular dystrophy program (Deramiocel)                
Research and development:                
Total research and development 7,310,101     5,430,428     24,854,222 16,674,567
Single reportable segment | Exosomes platform research                
Research and development:                
Total research and development 1,474,937     842,952     4,160,004 2,518,052
Single reportable segment | Other R&D segment expenses                
Research and development:                
Total research and development $ 1,987,401     $ 1,073,254     $ 5,131,018 $ 2,906,183